KEYTRUDA 25 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, JNJ-42756493, JNJ-42756493, JNJ-42756493, Docetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung
42756493BLC3001
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, JNJ-42756493, JNJ-42756493, JNJ-42756493, Docetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung for Advanced Urothelial Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Advanced Urothelial Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active